| Display title | Chemistry:Atagabalin |
| Default sort key | Atagabalin |
| Page length (in bytes) | 3,611 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 323375 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>OrgMain |
| Date of page creation | 02:06, 6 February 2024 |
| Latest editor | imported>OrgMain |
| Date of latest edit | 02:06, 6 February 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Atagabalin (PD-0200,390) is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α2δ calcium channels (1 and 2). It was under development as a treatment for insomnia, but was discontinued following unsatisfactory trial results. |
